Insight Molecular Diagnostics (IMDX) EBITDA (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of EBITDA data on file, last reported at -$4.4 million in Q1 2026.

• Quarterly EBITDA rose 35.09% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 20.54% YoY) and the FY2025 annual result came in at -$10.5 million, up 17.21% from the prior year.
• EBITDA retreated to -$4.4 million in Q1 2026 per IMDX's latest filing, from $17.1 million in the prior quarter.
• The five-year high for EBITDA was $17.1 million in Q4 2025, with the low at -$16.2 million in Q4 2023.
• Average EBITDA over 5 years is -$4.2 million, with a median of -$6.5 million recorded in 2023.
• The widest YoY moves for EBITDA: up 293.9% in 2023, down 410.09% in 2023.
• Insight Molecular Diagnostics' EBITDA stood at -$11.6 million in 2022, then slumped by 38.9% to -$16.2 million in 2023, then surged by 190.7% to $14.7 million in 2024, then increased by 16.81% to $17.1 million in 2025, then plunged by 125.74% to -$4.4 million in 2026.
• Business Quant data shows IMDX's EBITDA at -$4.4 million in Q1 2026, $17.1 million in Q4 2025, and -$11.0 million in Q3 2025.